BOLT - Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $10.1M
- Beta
- 1.12
- 52-Week Range
- 3.91-7.35
- CEO
- William Quinn
- Employees
- 52
- IPO Date
- Feb 5, 2021
- Exchange
- NASDAQ
BOLT Options Snapshot
Options pricing data for BOLT is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The BOLT overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked BOLT overview questions
- What is BOLT?
- BOLT is the ticker symbol for Bolt Biotherapeutics, Inc., a listed security. Bolt Biotherapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. Listed on NASDAQ. BOLT is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What are BOLT's key statistics?
- Bolt Biotherapeutics, Inc. (BOLT) carries a market capitalization of $10.1M, beta of 1.12 relative to the broader market, 52-week range of 3.91-7.35. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does BOLT belong to?
- Bolt Biotherapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare BOLT's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the BOLT data on this page?
- Options snapshots refresh after each trading session; if no snapshot is currently posted for BOLT, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).